Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Mar 13:8:59.
doi: 10.1186/1748-717X-8-59.

Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response

Affiliations
Clinical Trial

Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response

Daniel Habermehl et al. Radiat Oncol. .

Abstract

Purpose: Photon-based radiation therapy does currently not play a major role as local ablative treatment for hepatocellular carcinoma (HCC). Carbon ions offer distinct physical and biological advantages. Due to their inverted dose profile and the high local dose deposition within the Bragg peak, precise dose application and sparing of normal tissue is possible. Furthermore, carbon ions have an increased relative biological effectiveness (RBE) compared to photons.

Methods and materials: A total of six patients with one or more HCC-lesions were treated with carbon ions delivered by the raster-scanning technique according to our clinical trial protocol. Diagnosis of HCC was confirmed by histology or two different imaging modalities (CT and MRI) according to the AASLD-guidelines. Applied fractionation scheme was 4 × 10 Gy(RBE). Correct dose application was controlled by in-vivo PET measurement of β + -activity in the irradiated tissue shortly after treatment.

Results: Patients were observed for a median time period of 11.0 months (range, 3.4 - 12.7 months). Imaging studies showed a partial response in 4/7 lesions and a stable disease in 3/7 lesions in follow-up CT- and MRI scans. Local control was 100%. One patient with multifocal intrahepatic disease underwent liver transplantation 3 months after carbon ion therapy. During radiotherapy and the follow-up period no severe adverse events have occurred.

Conclusions: We report the first clinical results of patients with HCC undergoing carbon ion therapy using the rasterscanning technique at our institution. All patients are locally controlled and experienced no higher toxicities in a short follow-up period. Further patients will be included in our prospective Phase-I clinical trial PROMETHEUS-01 (NCT01167374).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Measurement of β+-activity at a dedicated PET/CT scanner after application of a dose of 10 Gy(RBE). Calculation of dose distribution with Syngo® RT planning (TPS).
Figure 2
Figure 2
(a). Treatment response after carbon ion irradiation of a HCC lesion after 4, 8 and 12 weeks (contrast enhanced MRI). Perifocal contrast enhancement indicates radiation-induced liver reaction. (b). Treatment response of the same patient after 4 and 12 weeks (contrast enhanced CT).

References

    1. Llovet JM, Ricci S, Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. doi: 10.1056/NEJMoa0708857. - DOI - PubMed
    1. Komatsu S, Fukumoto T, Demizu Y. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer. 2011;117:4890–4904. doi: 10.1002/cncr.26134. - DOI - PubMed
    1. Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005;15:279–283. doi: 10.1016/j.semradonc.2005.04.005. - DOI - PubMed
    1. Jianshe Y, Wenjian L, Xiaodong J. Survival and initial chromatid breakage in normal and tumour cells exposed in vitro to gamma rays and carbon ions at the HIRFL. Br J Radiol. 2006;79:518–521. doi: 10.1259/bjr/99734289. - DOI - PubMed
    1. Tan CH, Low SC, Thng CH. APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int J Hepatol. 2011;2011:519783. - PMC - PubMed

Publication types

Associated data